Leerink Partnrs Forecasts NeuroPace FY2029 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for NeuroPace in a report released on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky anticipates that the company will post earnings of $0.43 per share for the year. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

Several other analysts have also recently commented on the stock. JPMorgan Chase & Co. upped their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Wells Fargo & Company increased their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, UBS Group initiated coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $14.80.

NeuroPace Stock Performance

Shares of NeuroPace stock opened at $13.76 on Thursday. The firm has a fifty day moving average of $11.84 and a two-hundred day moving average of $8.86. The stock has a market capitalization of $410.71 million, a price-to-earnings ratio of -13.76 and a beta of 2.02. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.15. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The firm had revenue of $21.06 million during the quarter, compared to analysts’ expectations of $19.33 million. During the same quarter in the previous year, the company posted ($0.28) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Palumbo Wealth Management LLC acquired a new stake in shares of NeuroPace during the 4th quarter worth approximately $129,000. Financial Advocates Investment Management increased its stake in NeuroPace by 27.8% in the fourth quarter. Financial Advocates Investment Management now owns 23,000 shares of the company’s stock valued at $257,000 after purchasing an additional 5,000 shares in the last quarter. KCK LTD. bought a new stake in NeuroPace in the fourth quarter valued at $58,981,000. JPMorgan Chase & Co. grew its holdings in shares of NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after buying an additional 6,181 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after buying an additional 16,007 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now owns 87,062 shares in the company, valued at $1,306,800.62. This represents a 3.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 22.20% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.